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Abstract
Background: Drug use during pregnancy is difficult to ascertain, and maternal reports are likely to be inaccurate.
The aim of this study was to estimate the prevalence of illicit drug use among pregnant women by using maternal
hair analysis.
Methods: A toxicological analysis of hair was used to detect chronic recreational drug use during pregnancy. In 2007,
347 mother-infant dyads were included from the Hospital La Candelaria, Santa Cruz de Tenerife, Canary Islands (Spain).
Data on socioeconomic characteristics and on substance misuse during pregnancy were collected using a structured
questionnaire. Drugs of abuse: opiates, cocaine, cannabinoids and amphetamines were detected in maternal hair by
immunoassay followed by gas chromatography-mass spectrometry for confirmation and quantitation.
Results: Hair analysis revealed 2.6% positivity for cocaine and its metabolites. Use of cocaine during pregnancy was
associated with unusual behaviour with potentially harmful effects on the baby.
Conclusions: The results of the study demonstrate significant cocaine use by pregnant women in Canary Islands.
The data should be used for the purpose of preventive health and policy strategies aimed to detect and possibly
to avoid in the future prenatal exposure to drugs of abuse.
Background
As documented by the European Monitoring Centre on
Drugs and Drug Addiction (EMCDDA), drug use in
Spain shows a growing trend. The prevalence for cocaine
use appear to be at 3% [1], exceeding the rates reported
from USA [1,2]. When cocaine is used during pregnancy,
it can affect the cardiac and vascular systems of both, the
pregnant woman and the foetus. The effects of cocaine
on the foetal-placental unit can lead to placental detach-
ment or diminished blood flow with subsequent hypoxia
[3-5]. This could explain the frequency of spontaneous
abortions and foetal deaths observed in cocaine abusing
mothers [6].
The information in the literature regarding the preva-
lence of recreational drug use, specifically in pregnant
women is limited. Studies carried out in USA estimate
the rates of infants exposed prenatally to illicit drugs to
be between 6% and 40% of all live births [7-11]. In Spain,
the single large study focused on prenatal exposure to
drugs of abuse was conducted in Barcelona (alcohol,
tobacco and prescription drugs were not included); using
meconium testing an overall positivity of 10.9% for any
drug of abuse was shown [12].
It is well known that maternal self-reports on drug use
history proved to be unreliable therefore an objective bio-
logical marker which can yield a cumulative reflection of
long-term exposure to illicit drugs is needed. Since drugs
and their metabolites are permanently deposited in the
protein matrix of the hair, they can be detected in hair sev-
eral months after use, which provides an advantage over
other biological markers, such as urine or blood which are
limited to present only a “snapshot” of acute exposure to
drugs in the previous 24-48 hours [13-15]. Moreover,
maternal hair analysis allows for drug use studies in the
first trimester of pregnancy and has proven to be more
sensitive and stable compared to other matrices with large
exposure windows, such as meconium or neonatal hair
[16-19]. Acquiring maternal hair is easy and availability is
a non-issue.
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any medium, provided the original work is properly cited.Prenatal exposure to drugs of abuse is, of course, depen-
dent on maternal use during pregnancy. The exposure
data is different in every area, depending on socioeco-
nomic and geographical factors. Prevalence of prenatal
drug exposure in the Canary Islands is unknown. These
islands are located in the Atlantic Ocean, about 100 km
from the nearest point of the North African coast (south
west of Morocco). The economy of Canary Islands is
based on a few sectors: tourism and, to a much lesser
extent, farming and fishing. Tenerife, the largest and most
populated of the seven Canary Islands contains 43% of the
total population of the Canary Islands and it is well known
for being a holiday resort with a thriving night life, asso-
ciated with clubs, music and recreational drugs use.
The aim of this study was to estimate the prevalence of
illicit drug use among pregnant women in Tenerife by
using maternal hair analysis.
Methods
Subjects and samples
The study was carried out in the paediatric department of
the Hospital La Candelaria of Santa Cruz de Tenerife,
Spain, the main hospital of the island. Between June 2006
and June 2007, 347 mother-infant dyads agreed to partici-
pate in the study, without any refusal. Fifteen dyads were
not included due to different reasons: language issues,
death of newborn, critical illness of the mother. (N = 347).
The study was approved by the Institutional Ethical Com-
mittee, conducted in accordance with the Declaration of
Helsinki and signed informed consent was obtained from
participant parents. Parental socio-demographic character-
istics, life habits and drug habits during pregnancy were
recorded in previously validated questionnaires adminis-
tered to all participants the day after the delivery (Addi-
tional file 1) [10-12,15,17,20]. Obstetric history of the
mother was collected and neonatal anthropometric charac-
teristics using customised growth charts for birth weight
and height and clinical examination at birth were also
recorded.
On the day of delivery, a lock of scalp hair approxi-
mately 0.5 cm thick was cut from the posterior vertex of
the mothers as closely as possible to the skin. Since hair
grows at an approximate rate of 1 cm/month, in order to
document exposure in the last trimester of pregnancy, the
proximal segment (3 cm long) of the hair was considered
for the analysis of drugs of abuse. Hair was collected in
accordance with the SoHT (Society of Hair Testing)
recommendations and it was stored at room temperature
in a paper bag until analysis [21].
Determination of drugs of abuse in hair samples
Drugs of abuse including all the principal psychotropic
drugs and metabolites (6-monoacetylmorphine (6-
MAM), morphine and codeine for opiates; cocaine,
benzoylecgonine (BEG) and cocaethylene for cocaine;
Δ9-tetrahydrocannabinol (THC) and 11-nor-Δ9-tetrahy-
drocannabinol-9-carboxylic acid (THC-COOH) for can-
nabinoids; and amphetamine, methamphetamine, and
3,4 methylenedioxyamphetamine (MDMA) for ampheta-
mines were quantified.
Immunochemical screening for drugs of abuse in hair
was done with Siemens EMIT
® II Plus assay for opiates,
amphetamines and ecstasy and Microgenics CEDIA
®
assay for cocaine. All the samples with positive results
in the screening test (the cut-off values for opiates,
amphetamines, ecstasy, cocaine, and THC (directly, not
included in the previous screening) were 0.20 ng/mg,
0.50 ng/mg, 0.50 ng/mg, 0.20 ng/mg, and 0.50 ng/mg
respectively) for any drug and/or metabolite were ana-
lyzed by gas chromatography-mass spectrometry (GC/
MS) for confirmation and quantitation [9,15,21-23].
GC/MS analyses were carried out on an Agilent 6890 gas
chromatograph equipped with 5973 mass-selective detec-
tor and a 7673 automatic injector (Agilent Technologies,
Palo Alto, CA, USA). Limits of quantification in hair were:
0.2 ng/mg for 6-monoacetylmorphine, morphine and
codeine, 0.5 ng/mg for cocaine, BEG and cocaethylene;
0.1 ng/mg for Δ9-tetrahydrocannabinol, 0.2 pg/mg 11-nor-
Δ9-tetrahydrocannabinol-9-carboxylic acid and 0.2 ng/mg
for amphetamine, methamphetamine, and MDMA.
Statistical analysis
The continuous variables that followed a normal distri-
bution were presented as mean and standard deviation.
The categorical variables were presented as percentages
and were compared between variables with the Chi-
square. P value of less than 0.05 (two-tail) was consid-
ered to be statistically significant.
An initial descriptive statistical analysis of socio-demo-
graphic characteristics of mothers and anthropometric data
of the newborns was completed for the 347 mother-infant
dyads participating in the study. The group of positive
mother-infant dyads was compared with the group of nega-
tive mother-infant dyads for any drug. Statistical analysis
was performed considering the drug use (yes or no) as the
dependent variable. For the bivariate analysis of the data we
used the Student’s t test for independent groups to com-
pare between means of a continuous variable and the Chi-
square test to compare between categorical variables. Statis-
tical significance was set at p < 0.05. Database management
and statistical analysis were performed with SPSS v 14.0
(SPSS, Chicago, IL, USA).
Results
Socio-demographic characteristics and obstetric history
The mean age of the 347 mothers was 30 years. Seven-
teen percent were migrants, 85% from South-America.
With respect to the level of schooling, 29% had a
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Regarding obstetric history, 49% were at their first preg-
nancy, and 22% had previous spontaneous abortions.
Parental socioeconomic and demographic characteristics
in relation to results obtained by hair analysis are reported
in Table 1 Parental ethnicity and maternal or paternal
socioeconomic status were not associated with cocaine use
during pregnancy, but cocaine use appeared to be more
prevalent in Spanish mothers with unskilled jobs. On the
other hand, the exposure to cocaine during pregnancy was
associated with a significantly higher percentage of active
tobacco smoking fathers and the presence of other smo-
kers at home. There were no false negatives in our study
population comparing biomarkers to questionnaires
(admission of substance misuse). Finally, cocaine use dur-
ing pregnancy was associated with antidepressants use.
Concentrations levels of drugs of abuse in hair from
pregnant women
Of the 347 maternal hair samples minimum 3 cm long, 9
(2.6%) were positive for cocaine and/or BEG, its principal
metabolite. All the samples were negative for the other
drugs of abuse including cannabis, amphetamines,
methamphetamines, opiates, and MDMA.
Cocaine concentration in hair ranged between 0.25 and
2.06 ng/mg with a median value of 1.1 ng/mg and BEG
concentration ranged between 0.31 and 3.18 ng/mg with a
median value of 1.55 ng/mg. Benzoylecgonine/cocaine
ratios ranged between 0.05 and 1.61 with a median value
of 0.84.
Obstetric history and newborn anthropometric
characteristics at birth
The obstetric history and newborn anthropometric char-
acteristics are presented in Table 2. Maternal age was not
associated with substance misuse. Drug using mothers had
a higher number of previous abortions. There were no sig-
nificant differences with respect to newborn’s sex between
the positive and negative groups, but there was a trend of
more female newborns in both groups. Newborns from
cocaine users showed lower birth weight, crown-heel
length and cranial perimeter than newborns from non-
using mothers, but these differences did not reach signifi-
cance. There was no withdrawal syndrome or malforma-
tion in any of the drug exposed newborns.
Discussion
Prevalence of substance misuse among pregnant women
It is very difficult, based on the literature, to compare the
prevalence of substance misuse by pregnant women in dif-
ferent populations for many reasons: studies may relate to
different time periods, biological matrices have different
windows of detection and there are specific patterns of
substance misuse in different countries [24].
The European trend of increased cocaine use in the gen-
eral population, including pregnant women, could also be
observed in Tenerife. The results obtained in this study
are very similar to the results obtained in Barcelona
[12,20] and Glasgow (UK) [25] using meconium analysis.
Prevalence of drug exposure in our study is compared to
the results reported in other population studies
[12,20,25-28] and the results of the Spanish National Sur-
vey on Drug Abuse [1] in Table 3.
Hair testing as an analytical tool allowed for a more
accurate identification of newborns exposed in utero to
drugs of abuse compared to the identification based only
on maternal questionnaire. Our findings are in agreement
with the well-known under-reporting of tobacco smoke
and drug use by pregnant women, as documented in sev-
eral studies [11,26]. Overall, these data confirm the steady
cocaine use showed by EMCDDA using questionnaires
[1].
Surprisingly, we did not find any samples positive for
cannabis, in spite of the fact that it is the most abused
drug in European countries. According to data from the
Canarias Government, daily use of cannabis by adult
women in Tenerife is 1.0% [27]. It is worth mentioning
that, in theory, a single exposure to drugs could lead to a
positive result in hair analysis, but this occurrence has
been demonstrated in only 1 experiment in adults after
the administration of intravenous/intranasal cocaine, but
certainly not with cannabis use [28].
Finally, no opiates were detected in the Tenerife popula-
tion in contrast to the 4.7% opiates found in the Barcelona
study population. This might be due to the fact that the
population studied in Barcelona was from a low socio-
economic status using frequently a mixture of smoked
heroin and cocaine [29].
No positive cases of maternal alcohol use were recorded
by questionnaire in the exposed group of babies. This is in
agreement with the results of other studies based on ques-
tionnaires, however, based on biomarkers, it has been
shown that prenatal exposure to alcohol could reach 43%
[30].
Characteristics of the drug users and of the newborns
exposed in utero to drugs
Even though substance misuse has been associated with
low income and lack of education [31], we found no asso-
ciations with the level of schooling or profession. Our
study showed that drug using mothers present with beha-
vioural patterns with potentially harmful effects on the
child’s health (e.g. tobacco smoking, benzodiazepines and/
or antidepressants use) to a significantly higher extent.
Data from our study highlighted a higher rate of pre-preg-
nancy drug use (declared by questionnaire) among
tobacco smoking women compared to non-smoking
women. This tendency has been already reported in
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Mother’s hair positive for cocaine and/or
BEG (N = 9)
Mother’s hair negative for any drug of abuse
(N = 365)
Parental Nationality
Mother’s nationality
Spanish 9 (100.0%) 298 (81.7%)
Non-Spanish 0 0%) 67 (18.2%)
Father’s nationality
Spanish 9 (100.0%) 298 (81.7%)
Non-Spanish 0 (0%) 67 (18.2%)
Maternal age (years), mean (S.D.) 28.6 (6.0) 30.3 (5.3)
Mother’s Educational Level
Unfinished elementary school 4 (44.4%) 85 (23.2%)
Employed mother (yes/no)
No 2 (22.2%) 110 (30.1%)
Mother’s socioeconomic status
Managerial, professional & skilled (non-manual) 3 (33.3%) 101 (28.0%)
Skilled (manual) and partly skilled 5 (55.6%) 224 (61.3%)
Unskilled 1 (11.1%) 40 (10.9%)
Single Mother
Yes 0 (0%) 12 (3.3%)
Father’s Educational Level
Unfinished elementary school 4 (44.4%) 120 (33.2%)
Employed father (yes/no)
No 0 (0%) 25 (7.0%)
Father’s socioeconomic status
Managerial, professional & skilled (non-manual) 1 (11.1%) 101 (28.0%)
Skilled (manual) and partly skilled 7 (77.8%) 244 (66.9%)
Unskilled 1(11.1%) 20 (5.1%)
Habitat
Rural (< 10.000 inhab.) 1 (11.1%) 56 (15.3%)
Semi-rural (10 - 100.000 inhab.) 5 (55.6%) 127 (34.7%)
Urban (> 100.000 inhab.) 3 (33.3%) 182 (50.0%)
Maternal drug use at the visit
Past substance misuse, yes 5 (55.6%)** 47 (12.8%)
Cocaine use, yes 4 (44.4%)** 15 (4.2%)
Tobacco smoking
Mother 7 (77.8%)* 60 (16.3%)
Number of daily cigarettes, mean (S.D.) 6.5 (2.1) 7.2 (6.0)
Did you smoke before pregnancy?, yes 8 (88.8%)* 100 (27.3%)
Father 7 (77.8%)* 138 (37.9%)
Have been exposed to tobacco smoke during
pregnancy?
4 (44.4%) 101 (28.0%)
Other smokers in the presence of the pregnant
woman?
2 (22.2%)* 23 (6.3%)
Use of Antidepressants, yes (11.1%)* 8 (2.2%)
Alcohol use, yes 1 (0%) 15 (4.2%)
** P < 0.005 respect control group
* P < 0.05 respect control group
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Mother’s hair positive for cocaine and/or BEG
(N = 9)
Mother’s hair negative for any drug of abuse
(N = 365)
Previous pregnancies
No 4 (44.4%) 177 (48.5%)
1 2 (22.2%) 120 (32.8%)
> 2 3 (33.3%) 58 (15.9%)
Previous premature infants
Yes 0 (0%) 3 (0.9%)
Previous abortions
Yes 4 (44.4%) 85 (23.2%)
Children characteristics at birth
Gender, female 2 (22.2%) 193 (52.8%)
Gestational age (weeks), mean (S.
D.)
38.9 (1.1) 38.9 (1.5)
Prematurity 0 (0%) 25 (6.9%)
Weight at birth (g), mean (S.D.) 3199 (523) 3288 (499)
Length at birth (cm), mean (S.D.) 49.8 (2.6) 50.8 (2.7)
Cranial perimeter (cm), mean (S.
D.)
33.4 (1.6) 34,2 (1,5)
Outcomes at birth
Yes 3 (33.3%) 125 (34.1%)
Loss of foetal well-being 0 (0%) 4 (1.2%)
Risk of perinatal infection 3 (33.%)4 72 (19.8%)
Hypoglycaemia 0 (0%) 23 (6.3%)
Developmental dysplasia of the
hip
0 (0%) 5 (1.5%)
Other outcomes † 0 (0%) 6 (1.8%)
** P < 0.005 respect control group
* P < 0.05 respect control group
† including respiratory, cardiac and dermatological diseases
Table 3 Comparison of the prevalence of drug exposure in our study population with the one reported in the
questionnaire-based PNSD and the results reported by other population
Sherwood et al.
[25]
Pichini et al.
[12,22]
Williamson et al.
[23]
Mitsuhiro et al.
[24]
PNSD [1] Friguls et al
[26]
Joya et al.
Year 1999 2005 2006 2007 2009 2010 2011
Place London (UK) Barcelona (Spain) Glasgow (UK) Sao Pablo (Brazil) Spain Ibiza (Spain) Tenerife
(Spain)
Matrix Urine Meconium Meconium Hair Questionnaire Maternal hair Maternal hair
Trimester 1st 2nd - 3rd 2nd - 3rd 3rd No pregnant 3rd 3rd
Population general Low-income Low-income Low-income general general general
N 807 830 400 1000 23715 107 347
Cannabis
(%)
14.5 5.3 13.2 4.0 13.2 10.3 0
Cocaine (%) 0.37 2.6 2.7 1.7 3.0 6.4 2.6
MDMA (%) 0.1 1.4 0.9 0
Opiates (%) 1.36 4.7 0.1 0 0
Any drug
(%)
16.2 10.1 6.0 15.9 2.6
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We also found an association between maternal drug use
during pregnancy and maternal and paternal tobacco
smoking. Also, in our study, the correlation between
cocaine use and concurrent antidepressants use was signif-
icant. This association was reported on previously by Joya
et al [19] The finding requires a close follow-up of these
newborns [33] because of the high risk of withdrawal syn-
drome and adverse effects due to prenatal exposure not
only to cocaine but antidepressants as well.
According to some studies, prenatal exposure to cocaine
seems to have a negative effect on the child’s neurological
development and intellectual and emotional behaviour,
due to the effect of cocaine on the monoaminergic system
[34,35]. In our study, on the basis of self-reporting, the
newborns exposed to cocaine did not show (significant)
differences on somatometry characteristics. However, it is
well documented that ongoing maternal and environmen-
tal risk factors (e.g. drug abuse, violence, poor child care,
and maternal depressive symptoms) have been associated
with worse developmental outcomes in prenatally exposed
children [36,37]. The higher number of previous abortions
may be due to problem behaviour and lack of family plan-
ning in the case of these women [38].
Hair is a useful matrix to evaluate chronic substance
misuse during pregnancy
Even though 2.6% of the mothers had positive results for
cocaine use during the third trimester of pregnancy, less
than half of the mothers admitted drug use during preg-
nancy by questionnaire. This is not surprising, since the
tendency to under-report recreational drug use by preg-
nant women was highlighted previously [12,15,18]. Hair
testing for drugs provides a wide window of detection and
sample collection is not invasive [39]. GC/MS proved to
be a highly sensitive and specific technique for the detec-
tion of low concentrations of drugs [20,40]. Some authors
[14,15] concluded that, compared to meconium analysis,
hair analysis has higher sensitivity for detecting prenatal
use of cocaine and opiates. The method of maternal hair
analysis also allows for a more accurate estimation of the
timing of drug use compared to neonatal hair testing, as
neonatal hair has an irregular prenatal growth rate [24]. In
spite of the fact that hair testing is very useful in preva-
lence studies on prenatal exposure to drugs of abuse, there
are very few published reports to date on this topic.
Interventions for a pregnancy free of drugs of abuse and
for follow-up of prenatally exposed newborns
The results of our study justify for future screening for
drug use during pregnancy, that could provide the neces-
sary proof to start treatment for substance abuse which is
s i g n i f i c a n t l ym o r ee f f e c t i v ed u r i n gp r e g n a n c yt h a ni n
other periods in a woman’s life. Early recognition, early
intervention, timely enrolment into treatment, and a sus-
tained, long-term treatment regimen could minimize the
foetal impact of perinatal maternal illicit drug use and
may improve a woman’s prognosis for successful,
ongoing recovery from addiction. The development of a
screening and intervention protocol will undoubtedly
help medical care providers to make objective decisions
regarding their screening/testing/intervention practices
for women with substance abuse issues during pregnancy
and for their offspring [12,20]. We must emphasize that
these results are very important for public health and we
suggest some actions in order to be informed about the
prevalence of prenatal exposure to drugs of abuse and to
implement specific programs such as counselling with
brief intervention during pregnancy to avoid maternal
substance misuse and screening interventions during
pregnancy and at birth.
Limitations
The samples came from one single hospital, however, the
Hospital La Candelaria in Tenerife has the largest number
of births on the island, and by extension the entire archi-
pelago. There are no results for prenatal exposure to alco-
hol as the main legal drug of abuse, but the samples are in
the process of being analyzed and the results will be
presented.
Finally, hair analysis results could have been compared
to meconium analysis results as another standard tool to
detect prenatal chronic exposure to drugs of abuse. Meco-
nium is a direct neonatal biological matrix, but is informa-
tive only about the second (?) and third trimester of
pregnancy. Conversely, a sufficiently long maternal hair
will allow for information on the entire prenatal period; in
our study we used only the proximal 3 cm. segment of
hair.
Conclusions
These data underline the usefulness of hair analysis for the
diagnosis of chronic drug use during pregnancy and
demonstrate that there is significant hidden, undeclared
use of cocaine by pregnant women in the Canary Islands
that may cause multiple complications for both the baby
and the mother. The data can be used for the purpose of
preventive health and policy strategies aimed to avoid and
to detect prenatal exposure to drugs of abuse. Therefore,
it is essential to implement specific counselling and to
introduce screening methods during pregnancy. Finally,
uniform guidelines should be provided for health and
social service professionals.
Additional material
Additional file 1: Questionnaire. Questionnaire administered to all
participants the day after the delivery.
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